Seattle Genetics (SGEN) Tops Q2 EPS by 3c

Seattle Genetics (NASDAQ: SGEN) reported Q2 EPS of ($0.39), $0.03 better than the analyst estimate of ($0.42). Revenue for the quarter came in at $108.2 million versus the consensus estimate of $108.8 million.

As of June 30, 2017, Seattle Genetics had $473.0 million in cash, cash equivalents and investments.

2017 Financial Outlook

Seattle Genetics increased its expectations for 2017 ADCETRIS net product sales in the U.S. and Canada to a range of $290 million to $310 million.

For earnings history and earnings-related data on Seattle Genetics (SGEN) click here.

You May Also Be Interested In

• Rivian reports record Q3 deliveries, beats estimates, shares rise
• ConAgra Brands (CAG) Tops Q1 EPS by 13c, Beats on Revenue; Offers FY27 EPS Guidance
• Integra LifeSciences stock tumbles after cutting 2026 outlook